目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 33)
1.1 STUDY OBJECTIVES
1.2 BIOSIMILARS INDUSTRY DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 BIOSIMILARS MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 37)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 BIOSIMILARS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
FIGURE 6 ILLUSTRATIVE EXAMPLE OF REVENUE SHARE ANALYSIS AND SEGMENTAL ANALYSIS, 2022
FIGURE 7 ILLUSTRATIVE EXAMPLE OF REVENUE SHARE FOR DRUG CLASS & INDICATION, 2022
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 8 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
FIGURE 10 MARKET: CAGR PROJECTIONS, 2023-2028
FIGURE 11 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 MARKET: RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024-2027 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019-2027 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY (Page No. - 51)
FIGURE 13 BIOSIMILARS INDUSTRY, BY DRUG CLASS, 2023 VS. 2028 (USD MILLION)
FIGURE 14 BIOSIMILARS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 15 BIOSIMILARS INDUSTRY, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 54)
4.1 BIOSIMILARS MARKET OVERVIEW
FIGURE 16 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: MARKET, BY DRUG CLASS AND COUNTRY (2022)
FIGURE 17 MONOCLONAL ANTIBODIES AND US TO DOMINATE NORTH AMERICAN MARKET
4.3 MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 57)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Increasing demand for biosimilars
5.2.1.2 Launch of novel biosimilars
FIGURE 20 US: NUMBER OF APPROVED AND LAUNCHED BIOSIMILARS, 2015 TO 2022
5.2.1.3 Rising geriatric population and chronic disease incidence
FIGURE 21 GERIATRIC POPULATION, BY REGION, 2020 VS. 2030 VS. 2050 (MILLION)
FIGURE 22 ESTIMATED NUMBER OF NEW CANCER CASES FROM 2020 TO 2030
FIGURE 23 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
5.2.1.4 Abbreviated regulatory approval process and interchangeability
TABLE 5 APPROVED BIOSIMILARS WITH INTERCHANGEABLE DESIGNATION
FIGURE 24 COMPARISON OF REFERENCE PRODUCTS, BIOSIMILARS, AND INTERCHANGEABLE PRODUCTS
5.2.2 RESTRAINTS
5.2.2.1 Complexities in manufacturing
TABLE 6 COMPARISON OF DRUG DEVELOPMENT PROCESSES, BY TYPE
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Patent expiries of blockbuster biologics and research into new indications
TABLE 7 LIST OF KEY BIOLOGICS FACING PATENT EXPIRY
5.2.4 CHALLENGES
5.2.4.1 High competition and regulatory challenges
5.3 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS FOR BIOSIMILARS
5.4 ECOSYSTEM MARKET MAP
FIGURE 26 ECOSYSTEM MARKET MAP FOR BIOSIMILARS
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 8 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF SUPPLIERS
5.5.4 BARGAINING POWER OF BUYERS
5.5.5 INTENSITY OF COMPETITIVE RIVALRY
5.6 REGULATORY LANDSCAPE
TABLE 9 MARKET: REGULATORY LANDSCAPE
TABLE 10 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7 KEY CONFERENCES AND EVENTS, 2023
TABLE 15 MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2023
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 27 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF END USERS ON BUYING PROCESS
5.9 PATENT ANALYSIS
5.10 PIPELINE ANALYSIS
5.11 PRICING ANALYSIS
TABLE 16 BIOSIMILAR PRICE, BY INDICATION AND REGION
5.12 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

6 BIOSIMILARS MARKET, BY DRUG CLASS (Page No. - 83)
6.1 INTRODUCTION
TABLE 17 BIOSIMILARS INDUSTRY, BY DRUG CLASS, 2021-2028 (USD MILLION)
6.2 MONOCLONAL ANTIBODIES
TABLE 18 MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 19 MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 20 NORTH AMERICA: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 21 EUROPE: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 22 ASIA PACIFIC: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
6.2.1 INFLIXIMAB
6.2.1.1 Infliximab to dominate mAbs market
TABLE 23 MARKET FOR INFLIXIMAB, BY REGION, 2021-2028 (USD MILLION)
TABLE 24 NORTH AMERICA: MARKET FOR INFLIXIMAB, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 25 EUROPE: MARKET FOR INFLIXIMAB, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 26 ASIA PACIFIC: MARKET FOR INFLIXIMAB, BY COUNTRY, 2021-2028 (USD MILLION)
6.2.2 RITUXIMAB
6.2.2.1 Rising incidences of autoimmune diseases and cancer to boost market growth
TABLE 27 MARKET FOR RITUXIMAB, BY REGION, 2021-2028 (USD MILLION)
TABLE 28 NORTH AMERICA: MARKET FOR RITUXIMAB, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 29 EUROPE: MARKET FOR RITUXIMAB, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: MARKET FOR RITUXIMAB, BY COUNTRY, 2021-2028 (USD MILLION)
6.2.3 TRASTUZUMAB
6.2.3.1 Increasing breast cancer prevalence to drive market growth
TABLE 31 MARKET FOR TRASTUZUMAB, BY REGION, 2021-2028 (USD MILLION)
TABLE 32 NORTH AMERICA: MARKET FOR TRASTUZUMAB, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 33 EUROPE: MARKET FOR TRASTUZUMAB, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 34 ASIA PACIFIC: MARKET FOR TRASTUZUMAB, BY COUNTRY, 2021-2028 (USD MILLION)
6.2.4 ADALIMUMAB
6.2.4.1 Loss of patent exclusivity to drive research
TABLE 35 FDA APPROVAL AND EU LAUNCH STATUS OF BIOSIMILARS TO HUMIRA
TABLE 36 MARKET FOR ADALIMUMAB, BY REGION, 2021-2028 (USD MILLION)
TABLE 37 NORTH AMERICA: MARKET FOR ADALIMUMAB, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 38 EUROPE: MARKET FOR ADALIMUMAB, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 39 ASIA PACIFIC: MARKET FOR ADALIMUMAB, BY COUNTRY, 2021-2028 (USD MILLION)
6.2.5 OTHER MONOCLONAL ANTIBODIES
TABLE 40 MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 41 NORTH AMERICA: MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 42 EUROPE: MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 43 ASIA PACIFIC: MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
6.3 GRANULOCYTE COLONY-STIMULATING FACTOR
6.3.1 LAUNCH OF BIOSIMILARS TO PROMOTE MARKET GROWTH
TABLE 44 LIST OF APPROVED BIOSIMILARS FOR G-CSF
TABLE 45 MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2021-2028 (USD MILLION)
TABLE 46 NORTH AMERICA: MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 47 EUROPE: MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 48 ASIA PACIFIC: MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021-2028 (USD MILLION)
6.4 INSULIN
6.4.1 INCREASING INCIDENCE OF DIABETES TO DRIVE MARKET
TABLE 49 MARKET FOR INSULIN, BY REGION, 2021-2028 (USD MILLION)
TABLE 50 NORTH AMERICA: MARKET FOR INSULIN, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 51 EUROPE: MARKET FOR INSULIN, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 52 ASIA PACIFIC: MARKET FOR INSULIN, BY COUNTRY, 2021-2028 (USD MILLION)
6.5 ERYTHROPOIETIN
6.5.1 RISING INCIDENCE OF BLOOD DISORDERS TO AUGMENT MARKET GROWTH
TABLE 53 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
TABLE 54 MARKET FOR ERYTHROPOIETIN, BY REGION, 2021-2028 (USD MILLION)
TABLE 55 NORTH AMERICA: MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 56 EUROPE: MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 57 ASIA PACIFIC: MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021-2028 (USD MILLION)
6.6 RECOMBINANT HUMAN GROWTH HORMONE
6.6.1 INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS TO PROPEL MARKET
TABLE 58 MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2021-2028 (USD MILLION)
TABLE 59 NORTH AMERICA: MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 60 EUROPE: MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 61 ASIA PACIFIC: MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021-2028 (USD MILLION)
6.7 ETANERCEPT
6.7.1 APAC TO WITNESS HIGHEST GROWTH IN ETANERCEPT MARKET
TABLE 62 MARKET FOR ETANERCEPT, BY REGION, 2021-2028 (USD MILLION)
TABLE 63 NORTH AMERICA: MARKET FOR ETANERCEPT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 64 EUROPE: MARKET FOR ETANERCEPT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 65 ASIA PACIFIC: MARKET FOR ETANERCEPT, BY COUNTRY, 2021-2028 (USD MILLION)
6.8 FOLLITROPIN
6.8.1 INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT TO DRIVE MARKET
TABLE 66 MARKET FOR FOLLITROPIN, BY REGION, 2021-2028 (USD MILLION)
TABLE 67 NORTH AMERICA: MARKET FOR FOLLITROPIN, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 68 EUROPE: MARKET FOR FOLLITROPIN, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 69 ASIA PACIFIC: MARKET FOR FOLLITROPIN, BY COUNTRY, 2021-2028 (USD MILLION)
6.9 TERIPARATIDE
6.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO BOOST DEMAND
TABLE 70 MARKET FOR TERIPARATIDE, BY REGION, 2021-2028 (USD MILLION)
TABLE 71 NORTH AMERICA: MARKET FOR TERIPARATIDE, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 72 EUROPE: MARKET FOR TERIPARATIDE, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 73 ASIA PACIFIC: MARKET FOR TERIPARATIDE, BY COUNTRY, 2021-2028 (USD MILLION)
6.1 INTERFERONS
6.10.1 RISING INCIDENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
TABLE 74 MARKET FOR INTERFERONS, BY REGION, 2021-2028 (USD MILLION)
TABLE 75 ASIA PACIFIC: MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION)
6.11 ANTICOAGULANTS
6.11.1 WIDE RANGE OF APPLICATIONS TO DRIVE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS
TABLE 76 MARKET FOR ANTICOAGULANTS, BY REGION, 2021-2028 (USD MILLION)
TABLE 77 NORTH AMERICA: MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 78 EUROPE: MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 79 ASIA PACIFIC: MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2021-2028 (USD MILLION)
6.12 OTHER DRUG CLASSES
TABLE 80 MARKET FOR OTHER DRUG CLASSES, BY REGION, 2021-2028 (USD MILLION)
TABLE 81 ASIA PACIFIC: MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2021-2028 (USD MILLION)

7 BIOSIMILARS MARKET, BY INDICATION (Page No. - 123)
7.1 INTRODUCTION
TABLE 82 BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
7.2 ONCOLOGY
7.2.1 INCREASED APPROVALS AND LAUNCH OF BIOSIMILARS IN ONCOLOGY TO DRIVE MARKET
TABLE 83 MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
TABLE 84 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 85 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 86 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
7.3 INFLAMMATORY & AUTOIMMUNE DISEASES
7.3.1 CHANGES IN LIFESTYLES AND ENVIRONMENTAL CONDITIONS TO INCREASE DISEASE INCIDENCE
TABLE 87 MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2021-2028 (USD MILLION)
TABLE 88 NORTH AMERICA: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 89 EUROPE: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
7.4 CHRONIC DISEASES
7.4.1 HIGH BURDEN OF CVD AND DIABETES WORLDWIDE TO DRIVE MARKET GROWTH
TABLE 91 BIOSIMILARS INDUSTRY FOR CHRONIC DISEASES, BY REGION, 2021-2028 (USD MILLION)
TABLE 92 NORTH AMERICA: MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 93 EUROPE: MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 94 ASIA PACIFIC: MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
7.5 BLOOD DISORDERS
7.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS TO BOOST BIOSIMILAR DEMAND
TABLE 95 MARKET FOR BLOOD DISORDERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 96 NORTH AMERICA: MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 97 EUROPE: MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 98 ASIA PACIFIC: MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
7.6 GROWTH HORMONE DEFICIENCY
7.6.1 RISING USE OF BIOSIMILARS FOR TREATMENT TO SUPPORT MARKET GROWTH
TABLE 99 MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2021-2028 (USD MILLION)
TABLE 100 NORTH AMERICA: MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 101 EUROPE: MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 102 ASIA PACIFIC: MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021-2028 (USD MILLION)
7.7 INFECTIOUS DISEASES
7.7.1 MARKET FOR INFECTIOUS DISEASES TO GROW RAPIDLY IN ASIA PACIFIC
TABLE 103 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
TABLE 104 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
7.8 OTHER INDICATIONS
TABLE 105 MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2028 (USD MILLION)
TABLE 106 NORTH AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 107 EUROPE: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 108 ASIA PACIFIC: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

8 BIOSIMILARS MARKET, BY REGION (Page No. - 142)
8.1 INTRODUCTION
TABLE 109 BIOSIMILARS INDUSTRY, BY REGION, 2021-2028 (USD MILLION)
8.2 EUROPE
TABLE 110 EUROPE: LIST OF APPROVED BIOSIMILARS
FIGURE 29 EUROPE: BIOSIMILARS MARKET SNAPSHOT
TABLE 111 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 112 EUROPE: MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 113 EUROPE: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 114 EUROPE: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.2.1 GERMANY
8.2.1.1 Germany to dominate European biosimilars market
TABLE 115 GERMANY: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 116 GERMANY: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 117 GERMANY: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.2.2 UK
8.2.2.1 Increasing adoption of biosimilars to boost market
TABLE 118 UK: LIST OF APPROVED BIOSIMILARS
TABLE 119 UK: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 120 UK: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 121 UK: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.2.3 FRANCE
8.2.3.1 Rising geriatric population to drive market growth
TABLE 122 FRANCE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 123 FRANCE: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 124 FRANCE: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.2.4 ITALY
8.2.4.1 Favorable government policies to propel adoption of biosimilars
TABLE 125 ITALY: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 126 ITALY: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 127 ITALY: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.2.5 SPAIN
8.2.5.1 Favorable patient incentives to promote biosimilar use
TABLE 128 SPAIN: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 129 SPAIN: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 130 SPAIN: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.2.6 REST OF EUROPE
TABLE 131 REST OF EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 132 REST OF EUROPE: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 133 REST OF EUROPE: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.2.7 EUROPE: RECESSION IMPACT
8.3 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT
TABLE 134 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 135 ASIA PACIFIC: MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 136 ASIA PACIFIC: BIOSIMILARS INDUSTRY FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 137 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
8.3.1 CHINA
8.3.1.1 China to register highest growth in Asia Pacific market
TABLE 138 BIOSIMILARS APPROVED IN CHINA
TABLE 139 CHINA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 140 CHINA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 141 CHINA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.3.2 SOUTH KOREA
8.3.2.1 Favorable government initiatives to support growth
TABLE 142 SOUTH KOREA: LIST OF APPROVED BIOSIMILARS
TABLE 143 SOUTH KOREA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 144 SOUTH KOREA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 145 SOUTH KOREA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.3.3 INDIA
8.3.3.1 Increasing biosimilar launches and approvals to support market growth
TABLE 146 BIOSIMILARS APPROVED AND MARKETED IN INDIA
TABLE 147 INDIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 148 INDIA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 149 INDIA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.3.4 JAPAN
8.3.4.1 Large geriatric population to drive market growth
TABLE 150 JAPAN: LIST OF APPROVED BIOSIMILARS
TABLE 151 JAPAN: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 152 JAPAN: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 153 JAPAN: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.3.5 AUSTRALIA
8.3.5.1 Favorable regulatory changes and increasing disease incidence to propel growth
TABLE 154 AUSTRALIA: LIST OF APPROVED BIOSIMILARS
TABLE 155 AUSTRALIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 156 AUSTRALIA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 157 AUSTRALIA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.3.6 REST OF ASIA PACIFIC
TABLE 158 NEW ZEALAND: LIST OF APPROVED BIOSIMILARS
TABLE 159 MALAYSIA: LIST OF APPROVED BIOSIMILARS
TABLE 160 SINGAPORE: LIST OF APPROVED BIOSIMILARS
TABLE 161 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 162 REST OF ASIA PACIFIC: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 163 REST OF ASIA PACIFIC: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.3.7 ASIA PACIFIC: RECESSION IMPACT
8.4 NORTH AMERICA
TABLE 164 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 165 NORTH AMERICA: BIOSIMILARS INDUSTRY, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 166 NORTH AMERICA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 167 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
8.4.1 US
8.4.1.1 US to dominate North American biosimilars market
TABLE 168 US: LIST OF APPROVED BIOSIMILARS
TABLE 169 US: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 170 US: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 171 US: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.4.2 CANADA
8.4.2.1 Favorable government initiatives to support market
TABLE 172 CANADA: LIST OF APPROVED BIOSIMILARS
TABLE 173 CANADA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 174 CANADA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 175 CANADA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.4.3 NORTH AMERICA: RECESSION IMPACT
8.5 LATIN AMERICA
8.5.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET
TABLE 176 LATIN AMERICA: LIST OF APPROVED BIOSIMILARS
TABLE 177 LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 178 LATIN AMERICA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 179 LATIN AMERICA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.5.2 LATIN AMERICA: RECESSION IMPACT
8.6 MIDDLE EAST AND AFRICA
8.6.1 FAVORABLE REGULATORY REFORMS AND INFRASTRUCTURAL DEVELOPMENT TO FAVOR MARKET GROWTH
TABLE 180 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
TABLE 181 MIDDLE EAST AND AFRICA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
TABLE 182 MIDDLE EAST AND AFRICA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021-2028 (USD MILLION)
8.6.2 MIDDLE EAST AND AFRICA: RECESSION IMPACT

9 COMPETITIVE LANDSCAPE (Page No. - 216)
9.1 INTRODUCTION
9.2 STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 31 BIOSIMILARS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
9.3 REVENUE SHARE ANALYSIS
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2023
9.4 MARKET SHARE ANALYSIS
FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
TABLE 183 BIOSIMILARS MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION QUADRANT, 2022
9.5.1 STARS
9.5.2 EMERGING LEADERS
9.5.3 PERVASIVE PLAYERS
9.5.4 PARTICIPANTS
FIGURE 34 BIOSIMILARS MARKET: COMPANY EVALUATION QUADRANT, 2022
9.6 COMPETITIVE BENCHMARKING OF TOP 30 PLAYERS
9.6.1 COMPANY FOOTPRINT ANALYSIS (30 COMPANIES)
TABLE 184 BIOSIMILARS MARKET: COMPANY FOOTPRINT ANALYSIS
9.6.2 PRODUCT FOOTPRINT ANALYSIS (30 COMPANIES)
TABLE 185 BIOSIMILARS MARKET: PRODUCT FOOTPRINT ANALYSIS
9.6.3 REGIONAL FOOTPRINT ANALYSIS (30 COMPANIES)
TABLE 186 BIOSIMILARS MARKET: REGIONAL FOOTPRINT ANALYSIS
9.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
9.7.1 PROGRESSIVE COMPANIES
9.7.2 STARTING BLOCKS
9.7.3 RESPONSIVE COMPANIES
9.7.4 DYNAMIC COMPANIES
FIGURE 35 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
9.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES
TABLE 187 BIOSIMILARS MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 188 BIOSIMILARS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
9.9 COMPETITIVE SCENARIO AND TRENDS
9.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 189 BIOSIMILARS MARKET: PRODUCT LAUNCHES, JANUARY 2020-APRIL 2023
9.9.2 DEALS
TABLE 190 BIOSIMILARS MARKET: DEALS, JANUARY 2020-APRIL 2023
9.9.3 OTHER DEVELOPMENTS
TABLE 191 BIOSIMILARS MARKET: OTHER DEVELOPMENTS, JANUARY 2020-APRIL 2023

10 COMPANY PROFILES (Page No. - 231)
10.1 KEY MARKET PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 NOVARTIS AG
TABLE 192 NOVARTIS AG: BUSINESS OVERVIEW
FIGURE 36 NOVARTIS AG: COMPANY SNAPSHOT (2022)
10.1.2 PFIZER INC.
TABLE 193 PFIZER INC.: BUSINESS OVERVIEW
FIGURE 37 PFIZER INC.: COMPANY SNAPSHOT (2022)
10.1.3 AMGEN INC.
TABLE 194 AMGEN INC.: BUSINESS OVERVIEW
FIGURE 38 AMGEN INC.: COMPANY SNAPSHOT (2022)
10.1.4 DR. REDDY’S LABORATORIES LTD.
TABLE 195 DR. REDDY’S LABORATORIES LTD.: BUSINESS OVERVIEW
FIGURE 39 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2022)
10.1.5 ELI LILLY AND COMPANY
TABLE 196 ELI LILLY AND COMPANY: BUSINESS OVERVIEW
FIGURE 40 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
10.1.6 TEVA PHARMACEUTICAL INDUSTRIES
TABLE 197 TEVA PHARMACEUTICAL INDUSTRIES: BUSINESS OVERVIEW
FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT (2022)
10.1.7 FRESENIUS KABI AG
TABLE 198 FRESENIUS KABI AG: BUSINESS OVERVIEW
FIGURE 42 FRESENIUS KABI AG: COMPANY SNAPSHOT (2022)
10.1.8 STADA ARZNEIMITTEL AG
TABLE 199 STADA ARZNEIMITTEL AG: BUSINESS OVERVIEW
FIGURE 43 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT (2022)
10.1.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
TABLE 200 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
FIGURE 44 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)
10.1.10 F. HOFFMANN-LA ROCHE LTD
TABLE 201 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 45 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2022)
10.1.11 CELLTRION HEALTHCARE CO., LTD.
TABLE 202 CELLTRION HEALTHCARE CO., LTD.: BUSINESS OVERVIEW
FIGURE 46 CELLTRION HEALTHCARE CO., LTD.: COMPANY SNAPSHOT (2022)
10.1.12 SAMSUNG BIOLOGICS
TABLE 203 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
FIGURE 47 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022)
10.1.13 COHERUS BIOSCIENCES
TABLE 204 COHERUS BIOSCIENCES: BUSINESS OVERVIEW
FIGURE 48 COHERUS BIOSCIENCES: COMPANY SNAPSHOT (2022)
10.1.14 BIOCON
TABLE 205 BIOCON: BUSINESS OVERVIEW
FIGURE 49 BIOCON: COMPANY SNAPSHOT (2022)
10.1.15 AMEGA BIOTECH
TABLE 206 AMEGA BIOTECH: BUSINESS OVERVIEW
10.1.16 APOTEX INC.
TABLE 207 APOTEX INC.: BUSINESS OVERVIEW
10.1.17 BIOCAD
TABLE 208 BIOCAD: BUSINESS OVERVIEW
10.1.18 MABXIENCE
TABLE 209 MABXIENCE: BUSINESS OVERVIEW
10.1.19 PROBIOMED
TABLE 210 PROBIOMED: BUSINESS OVERVIEW
10.1.20 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.
TABLE 211 FUJIFILM KYOVA KIRIN BIOLOGICS CO., LTD.: BUSINESS OVERVIEW
10.1.21 INTAS PHARMACEUTICALS LTD.
TABLE 212 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
10.1.22 RELIANCE LIFE SCIENCES
TABLE 213 RELIANCE LIFE SCIENCES: BUSINESS OVERVIEW
10.1.23 KASHIV BIOSCIENCES, LLC
TABLE 214 KASHIV BIOSCIENCES, LLC: BUSINESS OVERVIEW
10.1.24 USV PRIVATE LIMITED
TABLE 215 USV PRIVATE LIMITED: BUSINESS OVERVIEW
10.1.25 AMNEAL PHARMACEUTICALS, INC.
TABLE 216 AMNEAL PHARMACEUTICALS INC.: BUSINESS OVERVIEW
10.2 OTHER PLAYERS
10.2.1 FORMYCON AG
10.2.2 POLPHARMA BIOLOGICS GROUP
10.2.3 AMPHASTAR PHARMACEUTICALS, INC.
10.2.4 ALVOTECH
10.2.5 UCB SA
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX (Page No. - 299)
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS